highthroughput
screen
nih
molecular
librari
sampl
collect
subsequ
optim
lead
dipeptidelik
seri
sever
acut
respiratori
syndrom
sar
main
proteas
inhibitor
led
identif
probe
compound
r
r
n
tertbutyl
phenyl
n
tertbutylamino
ethyl
pubchem
cid
unlik
major
report
coronaviru
inhibitor
act
via
coval
modif
enzym
r
noncoval
sarscov
inhibitor
moder
mw
good
enzym
antivir
inhibitori
activ
multicompon
ugi
reaction
util
rapidli
explor
structur
activ
relationship
within
enzym
bind
pocket
xray
structur
sarscov
bound
r
coronavirus
cov
envelop
larg
plusstrand
rna
virus
caus
medic
disord
common
cold
lower
respiratori
tract
infect
diarrhea
first
character
human
cov
strain
identifi
studi
extens
novel
sarscov
identifi
etiolog
agent
global
pandem
sever
acut
respiratori
syndrom
sar
atyp
pneumonia
led
progress
respiratori
failur
individu
death
juli
year
death
rate
approxim
sar
viru
abil
spread
persontoperson
via
respiratori
droplet
make
particularli
deadli
among
worldwid
pandem
threat
cooper
lead
nation
rigor
public
healthcar
campaign
fortun
success
control
outbreak
howev
reemerg
sarscov
still
consid
potenti
pandem
risk
potenti
new
strain
sar
could
sever
found
outbreak
sinc
two
addit
human
coronavirus
identifi
patient
around
world
virus
character
found
significantli
less
lethal
sarscov
recent
new
sarslik
viru
call
hcovemc
identifi
least
two
individu
one
die
sequenc
analysi
hcovemc
indic
viru
close
relat
bat
coronavirus
sarscov
therefor
possibl
futur
sarslik
pandem
remain
possibl
date
still
vaccin
antivir
agent
avail
prevent
treat
sarslik
infect
sarscov
genom
encod
larg
polyprotein
proteolyt
process
two
cystein
proteas
includ
proteas
papainlik
proteas
plpro
essenti
proteolyt
process
differ
cleavag
site
within
coronaviru
polyprotein
thu
vital
viral
replic
enzym
exist
primarili
dimer
solut
dimer
confirm
activ
speci
enzym
reaction
clone
express
recombin
sar
along
studi
show
essenti
viral
life
cycl
support
role
import
pathogen
compon
sarscov
therefor
viabl
target
antivir
drug
develop
sarscov
three
domain
residu
ii
residu
iii
residu
domain
ii
contain
activ
site
region
domain
domain
iii
domain
activ
site
contain
catalyt
dyad
consist
cystein
residu
act
nucleophil
histidin
residu
act
gener
acidbas
optim
octapeptidebas
inhibitor
use
mutat
comfa
model
report
recent
systemat
satur
mutagenesi
studi
conduct
posit
substrat
result
demonstr
strong
structureact
relationship
substrat
provid
basi
peptidomimet
inhibitor
design
xray
structur
sarscov
enzym
bound
hexapeptidyl
chloromethyl
keton
inhibitor
first
report
numer
peptid
structur
exist
context
target
antivir
drug
design
first
gener
proteas
inhibitor
maintain
peptid
natur
often
five
residu
length
bear
reactiv
warhead
group
terminu
form
coval
interact
figur
reactiv
warhead
group
includ
aldehyd
epoxyketon
halomethyl
keton
trifluoromethyl
keton
number
exampl
michael
acceptor
inhibitor
often
first
form
noncoval
interact
complex
enzym
posit
warhead
close
proxim
catalyt
cystein
attack
thiolat
anion
catalyt
cystein
onto
reactiv
atom
warhead
lead
format
coval
adduct
inactiv
enzym
one
compound
react
sar
report
ki
valu
nm
first
gener
inhibitor
achiev
submicromolar
activ
provid
valuabl
insight
structurebas
inhibitor
design
quickli
lead
nonpeptid
warheadbas
small
molecul
inhibitor
figur
effort
util
virtual
screen
approach
also
prove
success
lead
nonpeptid
inhibitor
eg
one
earli
compound
disclos
bear
cinnamyl
amid
cinanserin
figur
report
ic
valu
low
molecular
weight
nonpeptid
inhibitor
bear
reactiv
ester
keton
moieti
demonstr
moder
good
micromolar
inhibit
case
pyridyl
ester
achiev
inhibit
cellbas
assay
util
develop
use
coval
bound
inhibitor
unfortun
limit
due
potenti
offtarget
side
effect
toxic
despit
fact
current
commerci
avail
therapeut
act
covalentmodif
mechan
none
target
cystein
proteas
fact
proteas
class
serin
threonin
aspartyl
metallo
except
cystein
target
market
therapeut
suggest
get
coval
cysteineproteas
inhibitor
market
may
uniqu
challeng
therefor
research
focus
attent
identif
noncoval
inhibitor
legitim
noncoval
inhibitor
describ
date
limit
high
molecular
weight
peptidomimet
mw
amu
low
ligand
effici
includ
known
proteas
drug
origin
develop
hiv
proteas
effort
identifi
small
molecul
inhibitor
sar
inhibit
via
noncoval
mechan
possess
low
micromolar
potenc
good
cell
permeabl
screen
conduct
nih
molecular
librari
sampl
collect
compound
collabor
mesecar
laboratori
scripp
research
institut
molecular
screen
center
srimsc
molecular
librari
program
center
network
mlpcn
herein
describ
result
screen
campaign
prosecut
optim
effort
vanderbilt
special
chemistri
center
vscc
around
class
narylamido
acetamid
inhibitor
moder
molecular
weight
addit
collabor
effort
aid
xray
crystallographi
report
detail
molecular
interact
inhibitor
r
activ
site
describ
physicochem
ancillari
properti
r
enzym
also
known
nonstructur
protein
liber
coronaviru
polyprotein
selfcleavag
ntermin
ctermin
cleavag
site
although
autocatalyt
mechan
still
elucid
current
studi
suggest
involv
initi
dimer
event
two
unreleas
within
polyprotein
follow
seri
catalyt
step
liber
fulli
activ
dimer
enzym
proceed
process
remain
cleavag
site
polyprotein
sarscov
highli
activ
dimer
essenti
inact
monom
addit
affin
tag
addit
amino
acid
nand
ctermini
found
substanti
increas
dimer
dissoci
constant
k
dramat
decreas
enzymat
activ
enzym
therefor
express
purifi
sarscov
newli
design
express
construct
produc
authent
dimer
would
gener
viru
infect
cell
enzym
purifi
multistep
chromatograph
procedur
found
highli
activ
compound
cinanserin
report
highli
effect
noncoval
inhibitor
sarscov
ie
ic
valu
enzym
sought
use
compound
control
inhibitor
calcul
zfactor
highthroughput
screen
compound
librari
test
abil
cinanserin
inhibit
authent
version
sarscov
concentr
surprisingli
found
inhibit
enzym
next
test
abil
cinanserin
inhibit
enzym
human
coronaviru
mous
coronaviru
mhv
found
inhibit
proteas
cinanserin
concentr
sinc
kinet
inhibit
result
stand
contrast
chen
cowork
sought
explan
larg
discrep
potenc
upon
closer
examin
report
method
use
determin
ic
valu
cinanserin
found
express
construct
util
chen
cowork
incorpor
affin
tag
nterminu
extend
addit
residu
ntermin
affin
tag
never
remov
purifi
enzym
prior
kinet
studi
describ
addit
ntermin
ctermin
residu
sar
known
dramat
effect
increas
dissoci
constant
dimer
enzym
well
decreas
enzymat
activ
enzym
therefor
cinanserin
may
inhibit
nondimer
form
enzym
anoth
possibl
explan
triton
includ
assay
buffer
remov
potenti
promiscu
inhibit
caus
nonspecif
aggreg
protein
compound
test
cinanserin
inhibit
sarscov
mhv
concentr
cinanserin
presenc
absenc
triton
found
inhibit
enzym
either
case
ultim
unabl
use
cinanserin
control
inhibitor
sinc
inhibit
sarscov
mhv
proteas
observ
therefor
use
compound
figur
coval
modifi
posit
control
compound
highthroughput
screen
conduct
evalu
inhibit
peptid
cleavag
event
use
novel
fretbas
substrat
pubchem
aid
util
number
key
assay
featur
screen
campaign
signific
advantag
previou
ht
campaign
enzym
first
util
sarscov
construct
consist
nativ
sequenc
enzym
repres
vivo
postproteolyt
form
enzym
discuss
version
enzym
contain
tag
excess
amino
acid
known
drastic
reduc
catalyt
activ
enzym
second
maintain
high
concentr
fresh
reduc
agent
primari
assay
help
minim
elimin
coval
compound
primari
lead
final
util
highli
fluoresc
fretbas
peptid
substrat
compos
hilyt
fluor
fluoresc
label
attach
nterminu
quencher
dye
attach
cterminu
substrat
allow
excit
spectral
region
nm
help
elimin
spectral
overlap
compound
screen
moreov
high
fluoresc
quantum
yield
fluoresc
probe
suffici
low
turnov
number
enzym
yield
highli
sensit
assay
amen
screen
plate
format
low
km
substrat
concentr
primari
screen
molecular
librari
small
molecul
repositori
compound
time
screen
conduct
use
concentr
compound
primari
screen
produc
hit
greater
inhibit
excel
zprime
score
rel
low
hitrat
observ
among
hit
avail
reorder
test
confirm
screen
singl
second
screen
produc
activ
compound
greater
inhibit
subsequ
doserespons
test
compound
provid
activ
ic
valu
number
activ
counterscreen
sarscov
papainlik
proteas
plpro
also
potenti
target
sinc
vital
sarscov
matur
gener
major
ic
valu
substanti
greater
plpro
suggest
moder
good
select
inhibit
prior
initi
chemistri
phase
project
srimsc
perform
structur
cluster
analysi
confirm
activ
sever
interest
scaffold
cluster
hand
singleton
identifi
analysi
dipeptid
class
repres
hit
figur
one
two
analogu
ic
furyl
amid
seri
particular
interest
due
start
potenc
modular
natur
structur
properti
absenc
reactiv
function
found
within
typic
coval
modifi
within
furyl
scaffold
initi
compound
librari
array
design
base
upon
ht
data
use
ugi
mcc
multicompon
condens
strategi
scheme
initi
ugi
array
isocyanid
held
constant
afford
tertbutyl
group
r
substitu
r
maintain
either
found
origin
hit
also
identifi
toler
group
anoth
close
relat
dipeptid
cluster
ht
five
monom
select
r
amin
group
examin
modif
aryl
cyclopropyl
includ
potenti
aryl
replac
mean
reduc
mw
overal
lipophil
r
carboxyl
acid
compon
eight
monom
chosen
focus
exclus
substitut
aromat
heteroaromot
part
r
group
scan
acid
includ
control
sar
comparison
rel
compound
success
prepar
submit
test
disappointingli
two
ugi
librari
analogu
display
inhibit
level
greater
subsequ
determin
ic
valu
less
notabl
activ
analogu
exclus
within
subseri
concurr
synthet
plan
prepar
second
gener
ugi
librari
sarscov
crystal
suitabl
xray
diffract
analysi
obtain
inhibitor
bound
electron
densiti
associ
inhibitor
clearli
resolv
allow
accur
refin
posit
figur
bind
orient
overal
similar
known
coval
peptidomimet
inhibitor
inhibitor
preferenti
occupi
subpocket
enzym
r
enantiom
figur
orient
tertbutyl
amid
occupi
pocket
tertbutylanilido
group
occupi
deep
pocket
group
occupi
furyl
amid
act
p
group
comparison
mechanismbas
coval
inhibitor
pdb
code
occupi
subpocket
repres
schemat
figur
rel
inhibitor
addit
pocket
occupi
occupi
pocket
thu
rel
mw
reduc
amu
furthermor
lack
reactiv
warhead
electron
densiti
map
solvent
access
surfac
depict
bound
shown
figur
stereoview
inhibitorbound
structur
associ
interact
also
shown
figur
interestingli
ring
nitrogen
serv
hydrogen
bond
acceptor
within
subpocket
engag
nn
interatom
distanc
similar
hydrogenbond
interact
engag
retain
crystal
structur
furan
ring
oxygen
amid
carbonyl
oxygen
bifurc
interact
backbon
nh
although
distanc
amid
carbonyl
closer
appear
hydrogen
bond
base
upon
distanc
co
nh
geometri
ideal
fact
nh
nearli
coplanar
oxygen
atom
floor
pocket
catalyt
posit
beneath
amid
carbonyl
carbon
furan
oxygen
distanc
rather
uniqu
furyl
amid
interact
within
context
catalyt
residu
backbon
interact
set
understand
interact
prepar
second
chemic
librari
focus
exclus
p
group
hold
p
p
group
constant
result
initi
campaign
summar
figur
replac
piexcess
heterocycl
prove
success
ic
fulli
satur
tetrahydrofuran
select
set
acycl
analogu
less
activ
ic
substitut
furan
ring
neg
impact
activ
although
replac
furan
oxygen
atom
larger
sulfur
atom
relat
thiophen
weakli
toler
loss
relat
pyrrol
heterocycl
complet
inact
nearli
equipot
inhibit
imidazol
howev
encourag
thu
smaller
subset
analogu
prepar
complet
survey
fivememb
heterocycl
effort
identifi
analogu
similar
potenc
isom
interestingli
contrast
furyl
deriv
substitut
furyl
congen
sid
nearli
equipot
ic
sar
around
imidazol
prove
steep
nmethyl
c
substitut
analogu
less
activ
addit
methylen
spacer
deleteri
inhibit
subsequ
survey
p
replac
perform
order
identifi
altern
hydrogen
bond
acceptor
group
might
engag
retain
amid
p
group
among
variou
p
replac
examin
pyridazin
pyrazin
well
toler
although
improv
found
lead
compound
dramat
modif
around
pyridyl
ring
clearli
limit
reason
consist
inhibitor
bound
xray
structur
analogu
either
weak
inhibitor
inact
addit
pyridyl
analogu
permit
attempt
replac
p
also
unsuccess
identifi
compound
improv
inhibit
next
turn
chiral
stationari
phase
supercrit
fluid
chromatographi
sfc
separ
isol
singl
enantiom
figur
highli
specif
inhibit
found
singl
stereoisom
r
ic
identifi
first
elut
peak
chiral
sfc
addit
inhibitor
r
found
specif
inhibit
versu
plpro
inhibitor
r
subsequ
declar
mlpcn
probe
inhibitor
r
infer
r
stereoisom
base
upon
absolut
configur
observ
electron
densiti
map
xray
structur
complex
found
rotat
plane
polar
light
posit
direct
final
mechan
inhibit
sar
r
determin
competit
base
doublereciproc
plot
initi
rate
sar
catalyz
reaction
versu
variabl
concentr
substrat
fix
variabl
concentr
r
see
figur
supplement
materi
result
ki
valu
determin
equival
ic
valu
expect
sinc
ic
valu
inhibitor
determin
substrat
concentr
significantli
lower
km
valu
potenc
r
sarscov
deem
suffici
determin
antivir
potenc
compound
sarscov
urbani
infect
vero
cell
use
establish
antivir
assay
protocol
doserespons
curv
r
gener
mockinfect
sarscov
infect
cell
result
shown
figur
fit
data
present
figur
yield
antivir
ec
valu
second
experi
perform
one
month
later
yield
ec
valu
two
independ
experi
demonstr
result
noncoval
inhibitor
r
effect
inhibit
sarscov
replic
cell
cultur
search
literatur
noncoval
inhibitor
sarscov
also
antivir
data
associ
compound
compound
cinanserin
report
antivir
activ
report
sarscov
infect
vero
cell
treat
cinanserin
author
conduct
rna
quantit
assay
cell
cultur
media
report
log
reduct
indic
reduct
correl
titer
infecti
particl
author
also
control
cytotox
assay
report
cytotox
concentr
give
reduct
cc
cc
given
fact
high
cinanserin
concentr
major
vero
cell
like
kill
cinanserin
interpret
antivir
data
studi
deem
ambigu
next
compar
ec
r
valu
anoth
noncoval
compound
test
sarscov
infect
cell
target
sarscov
papainlik
proteas
plpro
known
compound
ic
plpro
enzym
nm
ec
valu
sar
infect
vero
cell
next
compar
ec
ic
ratio
noncoval
compound
r
respect
ratio
help
guid
compound
design
term
estim
valu
ic
need
achiev
order
achiev
pharmacolog
relev
effect
therefor
compar
valu
potent
coval
inhibitor
identifi
date
compound
ec
ki
valu
thu
noncoval
coval
inhibitor
achiev
similar
antivir
effect
base
upon
structur
inform
excel
proteas
inhibit
activ
sarscov
ubani
antivir
activ
r
elect
first
class
probe
candid
furyl
amid
seri
probe
r
found
highli
select
versu
plpro
ricerca
leadprofil
screen
discret
gpcr
ion
channel
transport
signific
activ
found
pb
buffer
neutral
ph
probe
r
found
excel
aqueou
solubl
extend
character
probe
inhibitor
r
analogu
cystein
proteas
sarscov
infect
cell
well
basic
dmpk
assay
assess
metabol
stabil
plasma
protein
bind
ongo
summari
describ
optim
molecular
interact
detail
potent
noncoval
inhibitor
sarscov
identifi
mlpcn
initi
four
compon
ugi
reaction
util
rapidli
gener
sar
optim
potenc
focus
bind
pocket
xray
analysi
r
complex
reveal
sever
key
interact
crucial
activ
particular
hydrogen
bond
interact
inhibitor
ring
nitrogen
activ
site
sidechain
locat
within
subpocket
probe
r
modest
molecular
weight
sarscov
inhibitor
demonstr
antivir
activ
noncoval
mechan
action
thu
provid
opportun
facilit
structurebas
design
inhibitor
refin
quest
potenti
novel
antisar
cov
therapi
collabor
effort
laboratori
continu
toward
identif
submicromolar
inhibitor
optim
properti
antivir
activ
potenti
test
anim
model
mlpcn
probe
freeli
avail
upon
request
nmr
spectra
record
bruker
mhz
instrument
meoh
cdcl
data
report
follow
chemic
shift
multipl
singlet
doublet
triplet
q
quartet
br
broad
multiplet
integr
coupl
constant
hz
low
resolut
mass
spectra
obtain
agil
seri
mass
spectromet
high
resolut
mass
spectra
record
water
qtof
apiu
analyt
thin
layer
chromatographi
perform
analtech
silica
gel
gf
micron
plate
analyt
hplc
perform
uv
detect
nm
along
elsd
detect
lcm
mm
use
either
min
gradient
tfach
cn
tfah
tfa
ch
cn
prepar
rphplc
purif
perform
custom
autom
purif
system
collect
trigger
mass
detect
use
gilson
inc
prepar
uvbas
system
use
phenomenex
luna
column
mm
id
acetonitril
unmodifi
water
tfa
custom
gradient
normalphas
silica
gel
prepar
purif
perform
use
autom
combiflash
companion
isco
solvent
extract
wash
chromatographi
hplc
grade
reagent
purchas
aldrich
chemic
co
use
without
purif
polymersupport
reagent
purchas
argonaut
technolog
biotag
seri
mm
screw
top
glass
tube
fit
magnet
stir
bar
equimolar
amount
mmol
carboxaldehyd
amin
carboxyl
acid
combin
methanol
ml
subsequ
treat
tertbutylisocyanid
mmol
mixtur
stir
ambient
temperatur
concentr
stream
nitrogen
well
ventil
hood
crude
mixtur
reconstitut
meoh
treat
argoresin
mptrisamin
biotag
inc
scaveng
appli
celit
pad
use
manifold
fit
polypropylen
filter
tube
capabl
filter
sampl
parallel
filtrat
purifi
directli
use
autom
massguid
rphplc
product
contain
fraction
concentr
give
final
product
puriti
judg
lcm
nm
elsd
h
nmr
repres
librari
member
final
librari
array
product
character
data
h
nmr
spectra
inhibit
found
support
inform
analogu
prepar
analog
manner
purifi
gilson
inc
prepar
uvbas
rphplc
chromatograph
lcm
data
repres
h
c
nmr
spectra
remain
analogu
found
support
inform
h
nmr
data
librari
provid
n
tertbutyl
phenyl
n
tertbutylamino
ml
scintil
equimolar
amount
mmol
acid
combin
methanol
treat
tertbutylisocyanid
mixtur
stir
ambient
temperatur
concentr
appli
dcm
solut
silica
column
purifi
gradient
etoac
hexan
racem
product
obtain
light
yellow
solid
express
construct
sarscov
enzym
design
produc
exact
code
region
enzym
releas
virusinfect
cell
express
construct
contain
hexahistidin
affin
tag
tev
proteas
site
also
recogn
cleav
sarscov
code
region
sarscov
codonoptim
synthes
biobas
canada
insert
pet
express
vector
enzym
express
e
coli
purifi
via
multistep
purif
protocol
employ
cobaltcharg
nickelcharg
metalchel
hitrap
affin
column
ge
health
scienc
deae
anionexchang
chromatographi
sizeexclus
chromatographi
purifi
sarscov
store
use
immedi
crystal
ht
assay
protocolth
primari
assay
began
addit
enzym
nm
final
concentr
assay
buffer
mm
hepe
mgml
bsa
tritonx
mm
dtt
ph
well
microtit
plate
next
nl
test
compound
dmso
inhibitor
final
concentr
dmso
dmso
alon
final
concentr
ad
appropri
well
plate
incub
minut
room
temperatur
incub
peptid
substrat
final
concentr
mm
hepe
ph
well
minut
incub
room
temperatur
ul
mm
acet
acid
ad
well
termin
assay
well
fluoresc
read
perkinelm
viewlux
use
fluorescein
filter
excit
wavelength
nm
nm
bandwidth
emiss
wavelength
nm
nm
bandwidth
data
normal
posit
control
inhibitor
well
contain
dmso
neg
control
protocol
conduct
singl
point
primari
pubchem
aid
triplic
point
secondari
pubchem
aid
confirmatori
dose
respons
assay
pubchem
aid
plpro
counterscreen
assay
protocolprior
assay
plpro
peptid
substrat
luciferas
detect
reagent
mix
assay
buffer
mm
hepe
mgml
bsa
mm
dtt
mm
edta
mm
magnesium
sulfat
ph
incub
min
assay
begun
dispens
plpro
enzym
nm
final
concentr
assay
buffer
assay
buffer
alon
well
microtit
plate
next
nl
test
compound
dmso
dmso
alon
final
concentr
ad
appropri
well
plate
incub
minut
room
temperatur
next
enzym
reaction
initi
dispens
preincub
mixtur
contain
plpro
peptid
substrat
luciferas
detect
reagent
um
final
substrat
concentr
final
well
luminesc
read
perkinelm
viewlux
minut
incub
room
temperatur
data
normal
posit
control
enzym
well
contain
dmso
neg
control
protocol
use
confirmatori
dose
respons
assay
pubchem
aid
detail
assay
protocol
data
gener
ht
probe
develop
found
pubchem
aid
pubchemncbinlmnihgovassayassaycgi
locea
crystal
xray
structur
determin
sarscov
complex
inhibitor
r
purifi
sarscov
concentr
mgml
buffer
compos
mm
hepe
ph
mm
enzym
incub
ice
final
concentr
mm
inhibitor
enzym
crystal
solut
ration
use
crystal
solut
consist
peg
mm
me
ph
mm
potassium
chlorid
mpd
crystal
trial
set
room
temperatur
use
method
hang
drop
vapor
diffus
significantli
better
crystal
format
observ
absenc
sodium
chlorid
crystal
sensit
small
fluctuat
ph
singl
wellform
crystal
use
soak
motherliquor
supplement
mm
inhibitor
room
temperatur
hour
mpd
use
cryoprotect
freez
crystal
liquid
nitrogen
store
synchrotron
time
avail
crystal
transfer
liquid
nitrogen
stream
dri
nitrogen
ga
k
xray
data
collect
xray
data
collect
ccd
detector
advanc
photon
sourc
argonn
nation
laboratori
beamlin
idf
life
sciencescollabor
access
team
lscat
xray
data
process
scale
use
sarscov
complex
crystal
singl
monom
asymmetr
unit
space
group
unit
cell
dimens
crystal
diffract
resolut
xray
intens
data
final
r
merg
data
complet
overal
addit
data
process
statist
provid
tabl
si
xray
intens
convert
structurefactor
amplitud
method
french
wilson
use
program
truncat
program
suit
initi
phase
model
determin
method
molecular
replac
use
program
molrep
program
suit
search
model
use
molecular
replac
consist
monom
sarscov
pdb
code
side
chain
intact
water
ligand
remov
final
optim
molecular
replac
solut
contain
singl
monom
asymmetr
unit
initi
round
combin
posit
bfactor
refin
perform
program
refmac
program
suit
use
maximumlikelihood
target
function
sigma
cutoff
structur
factor
amplitud
initi
differ
fourier
map
calcul
visual
use
program
coot
initi
fofc
differ
map
reveal
strong
residu
electron
densiti
peak
activ
site
inhibitor
r
molecular
model
inhibitor
built
use
monom
librari
sketcher
program
program
suit
monom
librari
descript
creat
refin
iter
round
refin
perform
water
molecul
ad
manual
strong
differ
densiti
peak
initi
refin
stage
peak
final
stage
refin
iter
refin
residu
electron
densiti
consist
two
dmso
molecul
buffer
solut
identifi
molecul
built
residu
densiti
includ
subsequ
refin
iter
refin
use
refmac
continu
r
work
r
free
valu
plateau
lowest
valu
respect
point
coordin
result
model
submit
tl
translationlibr
screw
server
gener
multigroup
tl
model
result
tl
group
visual
use
molecular
viewer
tl
websit
tl
group
chosen
two
round
tl
restrain
refin
perform
refmac
weight
term
set
result
final
r
work
r
free
valu
respect
justifi
inclus
tl
group
standard
refin
protocol
final
model
coordin
deposit
pdb
access
code
summari
final
xray
data
refin
statist
given
tabl
support
inform
sarscov
urbani
strain
use
experi
provid
center
diseas
control
prevent
mainten
vero
cell
use
studi
achiev
use
dulbecco
minim
essenti
media
dmem
gibco
supplement
unitsml
penicillin
gml
streptomycin
gibco
fc
altanta
biolog
antivir
experi
sarscov
urbani
carri
purdu
univers
use
biosafeti
level
suit
approv
biosafeti
protocol
establish
collabor
purdu
univers
institut
biosafeti
committe
growth
vero
cell
perform
seed
cell
onto
flatbottom
plate
densiti
approxim
cell
per
well
vero
cell
either
mockinfect
serumfre
dmem
infect
median
tissu
cultur
infect
dose
sarscov
urbani
per
well
serumfre
mem
incub
h
co
viral
inoculum
remov
incub
period
mem
supplement
fc
r
inhibitor
concentr
rang
ad
cell
incub
h
co
control
inhibitor
concentr
set
triplic
antivir
assay
perform
independ
least
separ
occas
cell
viabil
determin
approxim
h
infect
use
luminesc
cell
viabil
assay
promega
repres
first
gener
peptid
inhibitor
highlight
reactiv
warhead
group
red
side
chain
residu
p
blue
repres
second
gener
nonpeptid
inhibitor
highlight
potenti
warhead
group
red
select
sar
highlight
first
round
ugi
librari
xray
crystal
structur
cap
stick
green
carbon
sar
walley
stereo
view
hydrogen
bond
inhibitor
shown
black
dot
line
p
ugi
librari
subsequ
explor
azol
furan
analogu
inhibitor
data
indic
compound
greater
inhibit
test
concentr
ugi
strategi
monom
use
prepar
librari
hold
r
tbutyl
isocyanid
